IL6 and COVID-19: Other drugs borrowed by the “rheumatological world” have been used in COVID-19 because of their anti-inflammatory power: tocilizumab, an anti-IL6 antibody; anakinra, an anti-IL1 antibody; and baricitinib, an anti-JAK1 compound (16).